COMP <GO>
BBIO vs ABBV // FREE CASH FLOW YIELD
BridgeBio Pharma Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BBIO 4
— ABBV 10
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $74.95 (+5.97%) • MKT CAP: $13.83B
fcf-yield
-3.23%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBIO VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BBIO | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 95.80% | 70.20% | +25.60 | BBIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -3.23% | 3.47% | -6.70 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 126.30% | 8.60% | +117.70 | BBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.33 | -4.88 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | BBIO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 70.2 | 72.8 | -2.61 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 113.1x | -80.10 | BBIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $13.83B | $513.86B | -$500.03B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BBIO REV | ABBV REV | BBIO GROSS % | ABBV GROSS % | BBIO FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $502.1M | $61.16B | 95.8% | 70.2% | -$447.0M | $17.82B |
| FY 2024 | $221.9M | $56.33B | 98.3% | 70.0% | -$521.7M | $17.83B |
| FY 2023 | $9.3M | $54.32B | 44.0% | 44.0% | -$528.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBIO // BETA 1.00
ABBV // BETA 1.15